Home › Endometriumkanker › Massachusetts › Boston
Endometriumkanker klinische studies in Boston, MA
50 studies voor Endometriumkanker zoeken deelnemers op locaties in en rond Boston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruterenFase 3
- Dana-Farber Cancer Institute, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruterenFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekruterenFase 1/2
- Research Site, Boston
A Study of PHST001 in Advanced Solid Tumors
RekruterenFase 1
- Dana Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekruterenFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekruteren
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekruterenFase 1
- Research Site, Boston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RekruterenFase 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruterenFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruterenFase 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruterenFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RekruterenFase 3
- Tufts Medical Center ( Site 6052), Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
ALPINE: Maintenance Letrozole/Abemaciclib
RekruterenFase 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RekruterenFase 1/2
- Research Site, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruterenFase 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
RekruterenFase 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RekruterenFase 1
- Dana-Farber Cancer Institute, Boston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RekruterenFase 3
- Research Site, Boston
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
Rekruteren
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RekruterenFase 1
- Mass General Cancer Center, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekruterenFase 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruterenFase 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RekruterenFase 2
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekruterenFase 1
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruterenFase 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RekruterenFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruterenFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
RekruterenFase 1
- Massachusetts General Hospital, Boston
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
RekruterenFase 2
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
RekruterenGezonde vrijwilligers welkom
- Dana-Farber Cancer Institute, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RekruterenFase 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Rekruteren
- Dana Farber Cancer Institute, Boston
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
RekruterenFase 2
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RekruterenFase 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RekruterenFase 1/2
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
RekruterenGezonde vrijwilligers welkom
- Dana Farber Cancer Institute, Boston
Endometriumkanker studies in andere steden
- Houston, TX68 studies
- New York City, NY52 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Columbus, OH25 studies
- Oklahoma City, OK25 studies
- Chicago, IL25 studies
- Queens, NY25 studies
Andere studies in Boston
- Borstkanker112 studies
- Niet-kleincellige longkanker90 studies
- Kanker (alle vormen)85 studies
- Metastatische kanker63 studies
- Colorectale kanker63 studies
- Longkanker62 studies
- Eierstokkanker61 studies
- Prostaatkanker59 studies
- Depressie52 studies
- Hartfalen44 studies
- Acute myeloïde leukemie44 studies
- Aldermeesklierkanker43 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.